Wednesday, November 30, 2011
Omeros has reported that with its identification of compounds that interact
selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20% of the 77 Class A orphans. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros is initially targeting Class A orphan GPCRs.
Imperial College London and healthcare providers in North West London plan to form a partnership to improve the health and care of the local population of 1.9 million people.
Infinity Pharmaceuticals has reported that Mundipharma International has committed to providing over $50 million in funding in 2013 for the continued development of IPI-145, Infinity’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, as well as development candidates arising out of Infinity’s innovative discovery programs. An extension of the companies’ global strategic alliance, this funding reflects the broad commercial potential of IPI-145 in both hematologic cancers and inflammatory conditions as well as the continued productivity of Infinity’s discovery and development programs.